These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8109950)

  • 1. In vitro activity of a new carbapenem antibiotic, BO-2727, with potent antipseudomonal activity.
    Nakagawa S; Hashizume T; Matsuda K; Sanada M; Okamoto O; Fukatsu H; Tanaka N
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2756-9. PubMed ID: 8109950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I.
    Ubukata K; Hikida M; Yoshida M; Nishiki K; Furukawa Y; Tashiro K; Konno M; Mitsuhashi S
    Antimicrob Agents Chemother; 1990 Jun; 34(6):994-1000. PubMed ID: 2203313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Preclinical evaluation of meropenem, a new parenteral carbapenem].
    Edwards JR
    New Microbiol; 1995 Oct; 18 Suppl():19S-31S. PubMed ID: 8574929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
    Shibata K; Adachi Y; Kato E; Nagano R; Fuse A; Hashizume T; Ohtake N; Okamoto O; Nakagawa S
    J Antibiot (Tokyo); 1997 Feb; 50(2):135-8. PubMed ID: 9099222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of BMS-181139, a new carbapenem with potent antipseudomonal activity.
    Kessler RE; Fung-Tomc J; Kolek B; Minassian B; Huczko E; Gradelski E; Bonner DP
    Antimicrob Agents Chemother; 1995 Feb; 39(2):380-5. PubMed ID: 7726502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem.
    Ohba F; Nakamura-Kamijo M; Watanabe N; Katsu K
    Antimicrob Agents Chemother; 1997 Feb; 41(2):298-307. PubMed ID: 9021183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heteroaryliumthio substituted carbapenem derivatives: synthesis and in vitro activity of 1 beta-methyl-2-(dihydropyrrolotriazoliumthio)carbapenems.
    Wildonger KJ; Ratcliffe RW
    J Antibiot (Tokyo); 1993 Dec; 46(12):1866-82. PubMed ID: 8294246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I.
    Edwards JR; Turner PJ; Wannop C; Withnell ES; Grindey AJ; Nairn K
    Antimicrob Agents Chemother; 1989 Feb; 33(2):215-22. PubMed ID: 2655530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial properties of BO-2727, a new carbapenem antibiotic.
    Kato Y; Otsuki M; Nishino T
    J Antimicrob Chemother; 1997 Aug; 40(2):195-203. PubMed ID: 9301984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants.
    Wiedemann B; Zühlsdorf M
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():197-205. PubMed ID: 2681124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro activity of meropenem imipenem, the penem HRE 664 and ceftazidine against clinical isolates from West Germany.
    Bauernfeind A; Jungwirth R; Schweighart S
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():73-84. PubMed ID: 2509418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical characterization of novel tetrahydrofuranyl 1beta-methylcarbapenems: stability to hydrolysis by renal dehydropeptidases and bacterial beta-lactamases, binding to penicillin binding proteins, and permeability properties.
    Yang Y; Testa RT; Bhachech N; Rasmussen BA; Bush K
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2904-9. PubMed ID: 10582880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs.
    Sader HS; Jones RN
    Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):384-91. PubMed ID: 8354307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological activity of 1beta-methyl-2-[5'-isoxazoloethenylpyrrolidin-3'-ylthio]carbapenems.
    Kim DJ; Seo KJ; Lee KS; Shin KJ; Yoo KH; Kim DC; Park SW
    Bioorg Med Chem Lett; 2000 Dec; 10(24):2799-802. PubMed ID: 11133095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
    Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
    BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity and killing effect of DX-8739, a new carbapenem, compared with those of meropenem and imipenem against multiresistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
    Antimicrob Agents Chemother; 1995 Mar; 39(3):731-4. PubMed ID: 7793881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo antibacterial activities of meropenem, a new carbapenem antibiotic.
    Harabe E; Kawai Y; Kanazawa K; Otsuki M; Nishino T
    Drugs Exp Clin Res; 1992; 18(2):37-46. PubMed ID: 1644010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meropenem: a new carbapenem antimicrobial.
    Pryka RD; Haig GM
    Ann Pharmacother; 1994 Sep; 28(9):1045-54. PubMed ID: 7803882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers.
    Pitkin DH; Sheikh W; Nadler HL
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S238-48. PubMed ID: 9126699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.